• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for JAKAFI issued to INCYTE CORP

    9/28/21 5:20:01 AM ET
    $INCY
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $INCY alert in real time by email
    New Drug Application (NDA): 202192
    Company: INCYTE CORP
    • Email
    • Summary Review

    Products on NDA 202192

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    JAKAFI RUXOLITINIB PHOSPHATE EQ 5MG BASE TABLET;ORAL Prescription None Yes No
    JAKAFI RUXOLITINIB PHOSPHATE EQ 10MG BASE TABLET;ORAL Prescription None Yes No
    JAKAFI RUXOLITINIB PHOSPHATE EQ 15MG BASE TABLET;ORAL Prescription None Yes No
    JAKAFI RUXOLITINIB PHOSPHATE EQ 20MG BASE TABLET;ORAL Prescription None Yes No
    JAKAFI RUXOLITINIB PHOSPHATE EQ 25MG BASE TABLET;ORAL Prescription None Yes Yes

    Approval Date(s) and History, Letters, Labels, Reviews for NDA 202192

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    11/16/2011 ORIG-1 Approval Type 1 - New Molecular Entity PRIORITY; Orphan Label (PDF)
    Letter (PDF)
    Review
    Summary Review (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202192s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000SumR.pdf
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    09/27/2021 SUPPL-25 Labeling-Package Insert

    Label is not available on this site.

    09/22/2021 SUPPL-23 Efficacy-New Indication

    Label is not available on this site.

    01/14/2020 SUPPL-19 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202192Orig1s019Rpllbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2020/202192Orig1s019ltr.pdf
    05/24/2019 SUPPL-17 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/202192Orig1s017ltr.pdf
    10/26/2018 SUPPL-16 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202192s016lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/202192Orig1s016ltr.pdf
    12/06/2017 SUPPL-15 Labeling-Container/Carton Labels, Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s015lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202192Orig1s015ltr.pdf
    10/10/2017 SUPPL-14 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s014lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/202192Orig1s014ltr.pdf
    03/10/2016 SUPPL-12 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202192s012lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/202192Orig1s012ltr.pdf
    10/06/2015 SUPPL-11 Manufacturing (CMC)

    Label is not available on this site.

    12/02/2015 SUPPL-10 Manufacturing (CMC)

    Label is not available on this site.

    12/15/2014 SUPPL-9 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s009lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202192Orig1s009ltr.pdf
    12/04/2014 SUPPL-8 Efficacy-New Indication Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s008lblPi.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202192Orig1s008ltr.pdf
    05/30/2014 SUPPL-7 Manufacturing (CMC)

    Label is not available on this site.

    07/25/2014 SUPPL-6 Efficacy-Labeling Change With Clinical Data Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s006lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/202192Orig1s006ltr.pdf
    11/25/2013 SUPPL-5 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202192s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/202192Orig1s005ltr.pdf
    11/07/2013 SUPPL-4 Manufacturing (CMC)

    Label is not available on this site.

    06/12/2013 SUPPL-3 Efficacy-New Patient Population Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202192s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/202192Orig1s003ltr.pdf
    06/21/2012 SUPPL-1 Labeling-Package Insert Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202192s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2012/202192s001ltr.pdf

    Labels for NDA 202192

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    01/14/2020 SUPPL-19 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202192Orig1s019Rpllbl.pdf
    05/24/2019 SUPPL-17 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202192s017lbl.pdf
    10/26/2018 SUPPL-16 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202192s016lbl.pdf
    12/06/2017 SUPPL-15 Labeling-Container/Carton Labels Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s015lbl.pdf
    12/06/2017 SUPPL-15 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s015lbl.pdf
    10/10/2017 SUPPL-14 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202192s014lbl.pdf
    03/10/2016 SUPPL-12 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202192s012lbl.pdf
    12/15/2014 SUPPL-9 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s009lbl.pdf
    12/04/2014 SUPPL-8 Efficacy-New Indication Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s008lblPi.pdf
    07/25/2014 SUPPL-6 Efficacy-Labeling Change With Clinical Data Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202192s006lbl.pdf
    11/25/2013 SUPPL-5 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202192s005lbl.pdf
    06/12/2013 SUPPL-3 Efficacy-New Patient Population Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202192s003lbl.pdf
    06/21/2012 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202192s001lbl.pdf
    11/16/2011 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf
    Get the next $INCY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INCY

    DatePrice TargetRatingAnalyst
    6/16/2025$107.00Hold → Buy
    Stifel
    3/18/2025Buy → Neutral
    Guggenheim
    3/18/2025Outperform → Mkt Perform
    William Blair
    12/17/2024$77.00Neutral
    UBS
    10/29/2024$68.00 → $90.00Neutral → Buy
    BofA Securities
    10/1/2024$84.00Outperform
    Wolfe Research
    9/18/2024$83.00 → $74.00Buy → Hold
    Truist
    7/2/2024$52.00 → $48.00Market Perform → Underperform
    BMO Capital Markets
    More analyst ratings

    $INCY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & Chief Medical Officer Stein Steven H sold $251,786 worth of shares (3,706 units at $67.94), decreasing direct ownership by 3% to 102,886 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/23/25 3:56:25 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP & General Manager US Flannelly Barry P sold $91,602 worth of shares (1,340 units at $68.36), decreasing direct ownership by 4% to 35,149 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/17/25 4:06:01 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • EVP, GMAPPS Iyengar Vijay K sold $67,198 worth of shares (983 units at $68.36), decreasing direct ownership by 2% to 40,540 units (SEC Form 4)

      4 - INCYTE CORP (0000879169) (Issuer)

      7/17/25 4:05:27 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-25) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/27/2021. Application Category: NDA, Application Number: 202192, Application Classification: Labeling

      9/28/21 5:20:01 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for JAKAFI issued to INCYTE CORP

      Submission status for INCYTE CORP's drug JAKAFI (SUPPL-23) with active ingredient RUXOLITINIB PHOSPHATE has changed to 'Approval' on 09/22/2021. Application Category: NDA, Application Number: 202192, Application Classification: Efficacy

      9/23/21 5:11:12 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • FDA Approval for OPZELURA issued to INCYTE CORP

      Submission status for INCYTE CORP's drug OPZELURA (ORIG-1) with active ingredient RUXOLITINIB has changed to 'Approval' on 09/21/2021. Application Category: NDA, Application Number: 215309, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated

      9/22/21 11:16:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

      7/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte To Present Initial Data for its TGFβR2×PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025

      - Mini oral presentation to highlight initial Phase 1 data of INCA33890, a promising TGFβR2×PD-1-directed bispecific antibody, in patients with advanced or metastatic solid tumors - Oral presentation to feature initial data of INCB161734, a novel, selective and orally bioavailable inhibitor of G12D-mutated KRAS, in patients with advanced or metastatic solid tumors with KRASG12D mutations Incyte (NASDAQ:INCY) today announced that the Company will present key data from its oncology portfolio at the upcoming European Society of Medical Oncology (ESMO) Congress 2025, to be held October 17-21 in Berlin. "We're looking forward to presenting the latest findings across our oncology portfolio

      7/24/25 5:02:00 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Report Second Quarter Financial Results

      Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

      7/10/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Leadership Updates

    Live Leadership Updates

    See more
    • Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

      - Three-decade industry leader, former CEO of Karuna and Anthos and Chief Commercial Officer of Allergan, Bill Meury, joins Incyte as President and CEO - Hervé Hoppenot to retire after 11 years of leading Incyte through major expansion - Julian Baker elected Chairman of the Board of Directors Incyte (NASDAQ:INCY) today announced that the Company's Board of Directors has unanimously appointed Bill Meury as President and Chief Executive Officer (CEO) and a member of the Company's Board of Directors, effective immediately. Bill Meury succeeds Hervé Hoppenot who will retire from the Company after 11 years of service. Mr. Hoppenot will serve as an advisor to the CEO and will remain as a

      6/26/25 7:30:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Galapagos appoints Dr. Susanne Schaffert as non-executive independent Director to its Board

      Mechelen, Belgium; 12 June 2023, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that during its meeting of 12 June 2023, the Board of Directors co-opted Dr. Susanne Schaffert as non-executive independent Director. Dr. Schaffert replaces Dr. Rajesh Parekh who stepped down on 10 June 2023. After an extraordinary 27-year career at Novartis in various global roles, including commercialization, market access, investor relations, business development & licensing, acquisitions and company integration, Dr. Schaffert retired in 2022 as President of Novartis Oncology and Member of the Novartis Executive Committee. In that role, Dr. Schaffert ran a global $15 billion business acr

      6/12/23 4:01:00 PM ET
      $GLPG
      $INCY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
    • Incyte Names New Member to Its Board of Directors

      Incyte (NASDAQ:INCY) announces the appointment of Susanne Schaffert, Ph.D., as a new member of its Board of Directors. "On behalf of the Incyte Board of Directors, I am happy to welcome Susanne. Her extensive commercial, development and industry experience will greatly complement our Board and we look forward to Susanne's contributions to our continued growth and future success," said Hervé Hoppenot, Chief Executive Officer, Incyte. "I am very excited for the opportunity to join the Incyte Board of Directors and helping the organization in its commitment to leading scientific innovation and developing new medicines for patients in need. I look forward to being part of this dynamic Company

      10/4/22 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Financials

    Live finance-specific insights

    See more
    • Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

      – Total revenues of $1,216 million in the second quarter (Q2'25) (+16% Y/Y); total product revenues of $1,059 million in Q2'25 (+17%Y/Y) – Jakafi® (ruxolitinib) net product revenues of $764 million in Q2'25 (+8% Y/Y); raising full year 2025 guidance to a new range of $3,000 - $3,050 million [previously $2,950 - $3,000 million] – Opzelura® (ruxolitinib) cream net product revenues of $164 million in Q2'25 (+35% Y/Y) – Niktimvo™ (axatilimab-csfr) net product revenues of $36 million in the second quarter, demonstrating strong commercial execution; raising full year 2025 Other Oncology guidance to a new range of $500 - $520 million [previously $415 - $455 million] – Zynyz® (retifanlimab-

      7/29/25 7:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte to Report Second Quarter Financial Results

      Incyte (NASDAQ:INCY) announced today that it has scheduled its second quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 29, 2025. The schedule for the press release and conference call/webcast is as follows: Q2 2025 Press Release: July 29, 2025 at 7:00 a.m. ET Q2 2025 Conference Call: July 29, 2025 at 8:00 a.m. ET Domestic Dial-In Number: 877-407-3042 International Dial-In Number: 201-389-0864 Conference ID Number: 13754581 If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-6

      7/10/25 8:00:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Positive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

      Data demonstrates the potential for INCA033989 to modify disease by directly inhibiting and eliminating oncogenic mutCALR cells, while sparing healthy cells and restoring normal blood cell production In high-risk patients with essential thrombocythemia (ET) with a CALR mutation (mutCALR), 86% of INCA033989-treated patients at doses 400 mg and above achieved a complete or partial hematologic response with the majority (82%) realizing a complete response A reduction in peripheral blood mutCALR variant allele frequency (VAF) was observed in 89% of evaluable patients correlating with hematologic response Initial results demonstrate a favorable safety profile – no dose limiting toxicit

      6/15/25 3:15:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    SEC Filings

    See more
    • SEC Form 10-Q filed by Incyte Corp.

      10-Q - INCYTE CORP (0000879169) (Filer)

      7/29/25 4:01:59 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - INCYTE CORP (0000879169) (Filer)

      7/29/25 7:06:23 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 144 filed by Incyte Corp.

      144 - INCYTE CORP (0000879169) (Subject)

      7/21/25 4:01:11 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Incyte upgraded by Stifel with a new price target

      Stifel upgraded Incyte from Hold to Buy and set a new price target of $107.00

      6/16/25 7:42:04 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by Guggenheim

      Guggenheim downgraded Incyte from Buy to Neutral

      3/18/25 7:52:49 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Incyte downgraded by William Blair

      William Blair downgraded Incyte from Outperform to Mkt Perform

      3/18/25 7:52:29 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care

    $INCY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Incyte Corp.

      SC 13G - INCYTE CORP (0000879169) (Subject)

      10/17/24 9:39:00 AM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Incyte Corp.

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      6/14/24 6:23:05 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form SC 13D/A filed by Incyte Corp. (Amendment)

      SC 13D/A - INCYTE CORP (0000879169) (Subject)

      5/13/24 6:06:33 PM ET
      $INCY
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care